Abstract
Positively charged naturally occurring or engineered peptide nanofibrils (PNF) are effective enhancers of lentiviral and retroviral transduction, an often rate-limiting step in gene transfer and gene therapy. These polycationic PNFs are thought to bridge the electrostatic repulsions between negatively charged membranes of virions and cells, thereby enhancing virion attachment and infection. This study analyzes PNFs formed by the peptide AL1, a fragment of an immunoglobulin light chain associated with systemic AL amyloidosis. We found that negatively charged AL1 PNFs interact with viral particles to a comparable extent as positively charged PNFs. However, AL1 PNFs lacked cell-binding activity and consequently did not enhance retroviral infection. These findings demonstrate that virion capture and cell binding of PNFs are mediated by distinct mechanisms, offering avenues for the design of advanced PNFs with selective functions.
Introduction
A significant challenge in gene therapy and virology is the efficient delivery of viral vectors to target cells. Both viral envelopes and cell membranes possess net negative charges, resulting in electrostatic repulsion that hinders attachment and subsequent infection. To overcome this "electrostatic barrier," researchers have traditionally employed polycationic peptide nanofibrils (PNFs), such as SEVI (Semen-derived Enhancer of Viral Infection) or EF-C (Protransduzin®). These fibrils act as electrostatic bridges, coating both the virus and the cell to facilitate proximity. However, these bridges are often non-selective. This study investigates whether a net positive charge is strictly necessary for these interactions by examining AL1, a peptide derived from immunoglobulin light chains that forms negatively charged fibrils.
Methods
The AL1 peptide was synthesized and allowed to self-assemble into amyloid-like nanofibrils. Characterization was performed using:
- Transmission Electron Microscopy (TEM): To visualize fibril structure and interactions with viral particles.
- Zeta Potential Measurements: To determine the surface charge of the fibrils.
- Biological Assays: TZM-bl reporter cells were used to measure HIV-1 infection rates in the presence of varying PNF concentrations.
- Confocal Microscopy & Flow Cytometry: To assess the stability of fibril attachment to cell surfaces after washing steps.
Results
Charge Characterization
Zeta potential measurements confirmed that AL1 PNFs are negatively charged (approximately -15 mV), in stark contrast to the positively charged enhancers SEVI (~ +16 mV) and EF-C PNF (~ +12 mV). This confirms that AL1 PNFs do not share the polycationic nature of traditional transduction enhancers.
Infection Enhancement and Cell Binding
Despite their ability to sequester viral particles (as observed via TEM), AL1 PNFs failed to significantly enhance HIV-1 infection. While the positive controls SEVI and EF-C PNF boosted infection rates by up to 21-fold and 39-fold respectively, AL1 PNF showed only a marginal ~2-fold increase at the highest concentrations.
Flow cytometry and confocal microscopy revealed that the lack of infection enhancement is due to poor cell-binding stability. Over 80% of AL1 fibrils were removed from cell surfaces during standard washing procedures, whereas positively charged fibrils remained tightly bound. This suggests that while "positive patches" on the AL1 surface might be sufficient to grab onto highly negative lipids in viral membranes, they are insufficient for stable interaction with the cellular lipid bilayer.
Discussion
These findings demonstrate that the mechanisms governing virion capture and cell binding by PNFs are distinct and can be decoupled. The ability of negatively charged AL1 PNFs to sequester viruses without adhering to cells suggests a potential for engineering "smart" nanomaterials. Such materials could be developed into selective antivirals that sequester or inactivate viruses while leaving host cells unaffected. Future work may involve decorating these scaffolds with specific antibodies or membrane-disrupting agents to create targeted therapeutic delivery systems or highly specific viral traps.
Summary updated